glp 1 approved for mash The FDA has Wegovy (semaglutide) as a treatment metabolic-associated steatohepatitis (MASH) with moderate-to-advanced scarring, a serious liver condition affecting approximately 6% of US adults. Key highlights of drug development program Wegovy becomes first GLP-1RA to

The dose is tailored to the patients needs, and monthly follow-ups ensure a shared, team-based approach to your wellness goals

For those with active lifestyles, a powder with a higher concentration of electrolytes may be best

Steris Healthcare Pvt

Jugessur, A., Farlie, P

Adults should engage in at least 150 min per week of moderate-intensity exercise or 75 min per week of vigorous-intensity aerobic exercise to reduce ASCVD risk [19]

In May 2026, PureHealth Research has introduced a new natural dietary supplement featuring berberine, formulated to support the bodys native metabolic and GLP-1 (glucagon-like peptide-1) pathways amid rising global interest in weight management and metabolic health